TuHURA Biosciences, Inc./NV

Clinical/early-stage biotech — near-insolvent.

Strengths

• Liquidity — current ratio 0.8 (12th)

Risks

• Pre-revenue, deep losses — per metrics
• Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
• Binary clinical & funding risk — per 10-K

Notable findings

• Going concern• We have expressed substantial doubt about our ability to continue as a going concern
• Cash burnNegative free cash flow (-27.7M)
• Weak liquidityCurrent ratio 0.78 (<1)
• Chronic dilutionShare count +57%/yr over 1y (dilution, book value/share -9%)
• Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
• Exec changeRecent 8-K item 5.02 8-K ↗
• Pending merger” On October 18, 2024, Kintara completed its reverse merger transaction in accordance with the terms of the Agreement and Plan of Merger, dated as of April 2, 2024 (the “Kintara Merger Agreement”),
• Notable holderHeld by 3 notable fund(s): STATE STREET CORP, GOLDMAN SACHS GROUP INC, FMR LLC (as of 2026-03-31)